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days following the onset of clinical signs. 
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orrhagic fever virus and a new st;~~jn of fever are to be eliminated, methods of diag~ 
Ebola virus were isolated co'ncurrentlY,ifrom nosis need to be improved and implem(.mta~ 
a group of cynomolgus monkeys housed in a tion of control programs must be increased. 
quarantine facility in Reston, VA. The Ebola The purpose of this article is to summarize 
virus spread slowly within quarantine the virology, pathology, clinical manifesta-
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tions, and epidemiology of Ebola virus and 
to discuss methods of containing future out~ 
breaks of Ebola hemorrhagic fever. 
Virology 
Ebola virus is a bacilliform rod that contains 
a negative-sense RNA genome.7 . .)t is mor~ 
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Marburg virus pictured between 2 human liver 
cells at 75,000X magnification. 
phologically similar to, yet antigenically dis-
tinct from, the other member of the 
Filoviridae family, the Marburg virus. Dis-
covered in 1967, Marburg virus behaves 
similarly to Ebola virus because it also af-
fects primates, causing hemorrhagic fever. 
Both viruses were originally classified as 
members of the Rhabdoviridae family, but 
subsequent studies proved them to be dis-
tinct.s 
Ebola has three subtypes (Zaire, Sudan, 
and Reston) which have common as well as 
unique epitopes.9 History has shown that 
the individual subtypes have resulted in in-
fections of varying severity. The infectivity 
ofEbola virus is stable at room temperature 
(20°C) but is largely destroyed in 30 min-
utes at 60°C. The virus can also be inacti-
vated by ultraviolet and gamma radiation, 
lipid solvents, B-propiolactone, and commer-
cial hypochlorite and phenolic disinfectants. 
Due to its aerosol infectivity, high mortality 
rate, potential for person-to-person trans-
mission, and the absence of any known pre-
vention or treatment, Ebola virus is classi-
fied as a biosafety level 4 pathogen by the 
World Health Organization. Maximum con-
tainment facilities are required for alilabo-
ratory work.10 
Pathogenesis and Pathology 
Transmission of Ebola virus has been shown 
to occur through direct contact with infected 
blood, secretions, organs, or semen. Al-
though there has not been documentation to 
show aerosol transmission between humans, 
Spring, 1997 
EM of Ebola Zaire virus.: This is thc first photo 
ever taken, on 10/13176, by 'Dr. F.A. Murphy, now 
at UC·Davis, then at CDC. Diagnostic specimen 
in cell culture at 160,OOOX magnification. 
this was the primary mode of spread between 
the cynomolgus monkeys in Reston, VA.5 
Subsequent to transmission, the virus un-
dergoes an incubation period of2 to 21 days 
(4-10 days average). Afterward, abrupt ill-
ness begins.15 
The full pathogenesis of this disease is 
still not understood; however, once infection 
is established, the progression of disease is 
striking. With the Zaire subtype, 
intracytoplasmic vesiculation and mitochon-
drial swelling are followed by breakdown of 
cellular organelles. Along with the cyto-
, pathic changes come large proliferations of 
virions. The cytopathic effects of both the 
Sudan and Reston subtypes are usually less 
severe due to the slower rate of infection. 11 
Studies on monkeys have shown that the 
virus may replicate in organ parenchymal 
cells, macrophages, or endothelial cells. Dis-
seminated intravascular coagulation (DIC) 
frequently occurs, but in spite of that, it is 
not clear whether it is an active cause of the 
disease process or merely a result of organ 
necrosis and an inability by the liver to pro-
duce sufficient clotting factors.12 Shock is . 
often seen in filovirus-infected patients and 
is presumably due to substances such as tu-
mor necrosis factor (TNF-alpha) which may 
increase vascular permeability.13 
Monkeys, guinea pigs, suckling mice, 
and hamsters have all been experimentally 
infected with Ebola virus. In monkeys, 
Ebola-Zaire is highly virulent with an incu-
bation period of 4 to 16 days, leading to 
death. The target organs are the liver, 
spleen, lymph nodes, and lungs, all of which 
7 
undergo extensive necrosis.12 Interestingly, 
Ebola-Sudan is sometimes self-limiting in 
monkeys, and Ebola-Reston ordinarily is 
even less pathogenic. 1 Nevertheless, the 
Reston subgroup can kill. Death due to 
Ebola-Reston has a consistent finding of 
marked splenomegaly, often 3 to 4 times the 
normal size.6 
. The most prominent lesion found in hu-
mans is focal necrosis of the liver paren-
chyma. Gross pathologic changes due to 
Zaire and Sudan subtypes include hemor-
rh.agic diathesis into skin, mucous mem-
branes, visceral organs, and the lumen of the 
stomach . and intestine. Swelling of the 
spleen, lymph nodes, kidIieys, and brain are 
other consistent findings.I4 
Clinical Manifestations 
The first clinical sign noted in the Reston 
monkeys was an abrupt onset of anorexia in 
animals that otherwise appeared normal. A 
decrease in defecation followed, and some 
monkeys had puffy eyelids, lacrimation, na-
sal exudate, and coughing. Upon palpation, 
splenomegaly was apparent. These animals 
generally experienced death within 2 to 7 
days after the onset of clinical signs.6 
Humans experience sudden fever with 
other nonspecific signs of headache, malaise, 
and myalgia. Other early signs include 
bradyca~dia and conjunctivitis. Within 2 to 
3 days, nausea, vomiting, and diarrhea ap-
pear with thrombocytopenia and leukopenia. 
Hemorrhages in the gastrointestinal tract 
lead to hematemesis and melena. A consis-
tent finding around day 5 is a macropapular 
rash over the trunk. This is notable since it 
is not seen in other viral hemorrhagic fevers, 
with the exception of dengue and sometimes 
lassa. Death due to shock usually occurs 6 
to 9 days following the onset of clinical dis-
ease.I6 The similarity ofthese sigOs to other 
Mrican fevers negates the possibility of a 
diagnosis by clinical observations alone, 
which may account for the failure to recog-
nize Ebola virus until the early 1970's. 
Epidemiology 
The epidemiology of Ebola virus is mysteri-
ous. Present knowledge is based primarily 
on the major outbreaks in Sudan and Zaire 
in 1976 and the recent outbreak in Zaire in 
8 
1995. All of the index cases of these out-
breaks have died before investigations com.· 
menced, hence they all acquired the disea:se 
by unknown means. The discovery of Ebola 
virus in monkeys imported into the U.S. from 
the Philippines led many to believe that mon-
keys were the natural reservoir. The lack of 
evidence for nlonkey die-off's or for latent vi-
ral infection in non-human primates raises 
questions as to the validity of that theory.17 
Zoonosis from other mammals is a possibil-
ity. Ebolfl shares many characteristics with 
Lassa Fever, which is maintained by chr~mic 
infection of rodents in Africa. In addition, 
antibodies to Ebola virus were found in 
guinea pigs retrieved by Dr. Cairns in 1981.3 
While rodents may not be the true reservoir, 
this may be an indication that the virus is 
present in plant material they ingested, or 
was transferred by the bite· of an arthropod. 
If t~e reservoir is a mammal, the virus' im~ 
munosuPPl'essive characteristics, lack ofim-
mune recognition of the virus, and decreased 
cytopathogenicity after isolation in mamma-
lian cell cultures suggest that Ebola's exist-
ence in nature may involve persistent infec-
tion of a mammalian host.I4 
No matter the source, the progression of 
Ebola hemorrhagic fever epidemics has been 
perpetuated by person-to-person contact. 
During the latter stages of the illness, which 
is characterized by vomiting, diarrhea, and 
often hemorrhage, the risk for transmission 
is at its peak. Infection has not been reported 
in persons whose contact with an infected 
person solely occurred during the incubation 
period. In the 1976 Zaire epidemic, consid~ 
erable transmission was traced to contami-
nated syringes and needles at a hospital. 
Secondary transmission from patients cared 
for in their homes was only 4 to 11%. Con-
sidering that simple patient isolation proce-
dures interrupt virus spread, it is most likely 
that Ebola virus is spread by blood and body 
fluids };nit not aerosol droplets. IS In contrast, 
the spread of disease among monkeys in the 
Reston, VA facility was airborne.6 Sofarthis 
has not applied to humans. The.1995 epi-
demic in Zaire produced results similar to 
previous Mrican outbreaks. After the ini-
tial outbreak, the next wave of cases was gen-
erated among friends and family of those 
first infected at the Kikwit hospitals. Like-
wise, the second and third generation of in-
fections were generated from other friends 
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or relatives of the first generation of cases.15 
The limited secondary attack rate suggests 
that transmission is not-efficient. 
Control Fd Treatment 
The elimination of all future cases of Ebola 
hemorrhagic fever is impossible without bet.-
ter knowledge concerning the natural his-
tory of the disease. Until efforts are success-
ful in locating the natural reservoir, no 
progress can be ma~e in eradicating the vi:. 
ruB from the environment. Humans will con-
tinue to come into contact with the ,source, 
and sporadic cases will be unavoidable. Vac-
cines may be the only tool which can pre-
vent further cases without knowledge of the 
source. Safe effective vaccines would be h~lp­
fu1 in preventing chance infections and in-
valuable for health professionals dealing 
with infected patients. ' 
At the moment, the primary weapons 
against epidemics are educating the public 
about Ebola virus and traJning health care 
workers to follow the guidelines for manag-
ing patients with suspected hemorrhagic fe-
ver.19 It has been shown in the past that 
the primary focus for virus spread has been 
the area where patient care has been given 
(i.e., hospitals and homes). Likewise, it has 
been shown that quarantine procedures are 
very effective in eliminating transfer of the· 
disease. Strict barrier nursing techniques 
should be practiced. Particular emphasis 
should be given to high-risk nursing proce-
dures such as placing intravenous lines and 
handling of body fluids. Hospital staff should 
all be equipped with gowns, gloves, and 
masks. Anyone coming into close physical 
contact with an infected individual without 
protection should be considered exposed and 
put under surveillance.1s 
While use oness-than-sterile technique 
may be common in African hospitals, the 
main problem has been associated with dif-
ficulties in diagnosis of the disease_ By the 
time management procedures have been 
implemented, the Ebola virus has already 
spread to those associated with the case. 
Development of an easy and accurate method 
of detection is essential to early diagnosis 
and prevention of spread. Clinical diagnos-
tics are helpful but not conclusive. Vll'US iso-
lation is potentially useful but very expen-
sive. Visualization by electron microscope 
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is time consuming. At this time, serologic 
diagnosis appears to be the key to identify-: 
ing Ebola virus infection. 
The most widely used assay for antibod-
ies to filoviruses is indirect fluorescent anti-
body (!FA). Although tIns technology has 
been useful, its results have occasionally 
been misleading. It has led to misdiagnosis 
of diseases thought to be due to filoviruses 
and has shown a high prevalence of antibod-
ies to Ebola virus in the absence of any rec-
ognized disease.20 A newly developed direct 
immup.oglobulin (IgG) enzyme-linked 
immunosorbent assaY-,.{ELISA) using in-
fected Vero cells adsorhed to plastic plates 
may be the final soluti~n, as it is both more 
sensitive and specific than !FA. ELISA ap-
parently has correctly confirmed all known 
positive tested sera and has given negative 
results to sera highly unlikely to have been 
expose(!l to Ebola virus.21 In both regards 
the IFAhas given contrary results. In addi-
tion, an antigen capture ELISA has been 
developed that is inexpensive and will de-
tect low concentrations ofvirus antigen. This 
may be useful in the search for reservoir 
hosts, as well as screening animals entering 
into the U.S. . 
Treatment of Ebola hemorrhagic fever 
has been highly ineffective. One patient with 
a laboratory-acquired Ebola virus infection 
survived after being treated with 450 ml of 
plasma from convalescent patients and 6 
million units ofleukocyte interferon daily for 
14 days.22 Unfortunately, trials with these 
treatments in monkeys showed poor results. 
Due to complications, supportive therapy is 
extremely difficult. There are problems with 
secondary bacterial infection and acid-base 
and electrolyte management. Other compli-
cations, such as hypoxia, shock, and blood 
loss must be managed. Intravenous heparin 
therapy may be beneficial before hemorrhage 
has begun. After the onset of hemorrhage, . 
platelets and clotting factors should be given. 
As the case fatality rates indicate, therapy 
is often in vain. 
Conclusion 
Like most diseases, prevention is the best 
medicine. Obviously, research needs to con-
tinue to ascertain the constitution of Ebola 
virus and the consequence of infection in 
mammals. Nevertheless, if epidemic preven-
9 
tion is the primary focus, efforts need to be 
concentrated toward implementing contain~ 
ment guidelines in the face of an outbreak 
in a timely fashion, and discovering the res~ 
ervoir of Ebola virus. The solutions to ac~ 
complishing these goals are educating the 
public in regard to the signs ofEbola hemor-
rhagitl fever and developing a practical and 
effeCtive method of identifying infected per-
sons and carriers of the virus. 
Editor's Note 
A recent report in Science News (vol. 150, 
Nov. 9, 1996, p. 294) stated that Robert 
Swanepoel and colleagues have demon-
strated that bats are capable of carryhlg 
Ebola after experimental inoculation with~ 
out becoming ill. It is possible that the bat 
may later· be shown to serve as a natural 
reservoir in the wild .• 
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